| Biological properties of extracellular vesicles and their physiological functions M Yáñez-Mó, PRM Siljander, Z Andreu, A Bedina Zavec, FE Borràs, ... Journal of extracellular vesicles 4 (1), 27066, 2015 | 4056 | 2015 |
| BET bromodomain inhibition as a therapeutic strategy to target c-Myc JE Delmore, GC Issa, ME Lemieux, PB Rahl, J Shi, HM Jacobs, E Kastritis, ... Cell 146 (6), 904-917, 2011 | 2851 | 2011 |
| Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study LH Nguyen, DA Drew, MS Graham, AD Joshi, CG Guo, W Ma, RS Mehta, ... The Lancet Public Health 5 (9), e475-e483, 2020 | 2055 | 2020 |
| Targeting apoptosis pathways in cancer therapy IM Ghobrial, TE Witzig, AA Adjei CA: a cancer journal for clinicians 55 (3), 178-194, 2005 | 1786 | 2005 |
| Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma PG Richardson, E Weller, S Lonial, AJ Jakubowiak, S Jagannath, ... Blood, The Journal of the American Society of Hematology 116 (5), 679-686, 2010 | 993 | 2010 |
| Ibrutinib in previously treated Waldenström’s macroglobulinemia SP Treon, CK Tripsas, K Meid, D Warren, G Varma, R Green, ... New England Journal of Medicine 372 (15), 1430-1440, 2015 | 874 | 2015 |
| BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression AM Roccaro, A Sacco, P Maiso, AK Azab, YT Tai, M Reagan, F Azab, ... The Journal of clinical investigation 123 (4), 1542-1555, 2013 | 770 | 2013 |
| Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma TE Witzig, SM Geyer, I Ghobrial, DJ Inwards, R Fonseca, P Kurtin, ... Journal of Clinical Oncology 23 (23), 5347-5356, 2005 | 611 | 2005 |
| Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma Y Alsayed, H Ngo, J Runnels, X Leleu, UK Singha, CM Pitsillides, ... Blood 109 (7), 2708-2717, 2007 | 540 | 2007 |
| Genomic complexity of multiple myeloma and its clinical implications S Manier, KZ Salem, J Park, DA Landau, G Getz, IM Ghobrial Nature reviews Clinical oncology 14 (2), 100-113, 2017 | 480 | 2017 |
| CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy AK Azab, JM Runnels, C Pitsillides, AS Moreau, F Azab, X Leleu, X Jia, ... Blood, The Journal of the American Society of Hematology 113 (18), 4341-4351, 2009 | 465 | 2009 |
| MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma AM Roccaro, A Sacco, B Thompson, X Leleu, AK Azab, F Azab, J Runnels, ... Blood, The Journal of the American Society of Hematology 113 (26), 6669-6680, 2009 | 369 | 2009 |
| Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma RH Prabhala, D Pelluru, M Fulciniti, HK Prabhala, P Nanjappa, W Song, ... Blood, The Journal of the American Society of Hematology 115 (26), 5385-5392, 2010 | 368 | 2010 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 367 | 2016 |
| Bone marrow microenvironment in multiple myeloma progression S Manier, A Sacco, X Leleu, IM Ghobrial, AM Roccaro Journal of Biomedicine and Biotechnology 2012, 2012 | 361 | 2012 |
| A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma TE Witzig, CB Reeder, BR LaPlant, M Gupta, PB Johnston, IN Micallef, ... Leukemia 25 (2), 341-347, 2011 | 351 | 2011 |
| Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features AK Azab, J Hu, P Quang, F Azab, C Pitsillides, R Awwad, B Thompson, ... Blood, The Journal of the American Society of Hematology 119 (24), 5782-5794, 2012 | 331 | 2012 |
| Targeting the bone marrow microenvironment in multiple myeloma Y Kawano, M Moschetta, S Manier, S Glavey, GT Görgün, AM Roccaro, ... Immunological reviews 263 (1), 160-172, 2015 | 329 | 2015 |
| Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180 SP Treon, L Ioakimidis, JD Soumerai, CJ Patterson, P Sheehy, M Nelson, ... Journal of Clinical Oncology 27 (23), 3830, 2009 | 307 | 2009 |
| The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients SP Treon, JJ Castillo, AP Skarbnik, JD Soumerai, IM Ghobrial, ... Blood 135 (21), 1912-1915, 2020 | 284 | 2020 |
